CALGB/SWOG 80405: Phase III Trial of Irinotecan/5-FU/Leucovorin (FOLFIRI) or Oxaliplatin/5-FU/Leucovorin (mFOLFOX6) with Bevacizumab (BV) or Cetuximab (CET) for Patients (PTS) with KRAS Wild-Type (WT) Untreated Metastatic Adenocarcinoma of the colon
- Citation:
- Ann Oncol vol 25 (supple 2) ii112-ii113
- Meeting Instance:
- ESMO GI 2014
- Year:
- 2014
- Type:
- Abstract
- Sub type:
- Oral
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pub
- Note:
- Presented at ESMO 16th World Congress on Gastrointestinal Cancer, 25–28 June 2014, Barcelona, Spain
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Parents:
- None
- Children:
- 2637
- Pharmas:
- Grants:
- Corr. Author:
- A. Venook
- Authors:
- A. Venook D. Niedzwiecki H.J. Lenz F. Innocenti M.R. Mahoney B. O'Neil J. Shaw B. Polite H. Hochster J. Atkins R. Goldberg R. Mayer R. Schilsky M. Bertagnolli C. Blanke Cancer and Leukemia Group B SWOG ECOG
- Networks:
- Study
- CALGB-80405
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: